Singular Historical Balance Sheet

OMIC Stock

USD 19.82 0.07 0.35%

Trend analysis of Singular Genomics Systems balance sheet accounts such as Total Current Liabilities of 22.1 M provides information on Singular Genomics' total assets, liabilities, and equity, which is the actual value of Singular Genomics Systems to its prevalent stockholders. By breaking down trends over time using Singular Genomics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Singular Genomics Systems latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Singular Genomics Systems is a good buy for the upcoming year.

Singular Genomics Inventory

9.57 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Singular Genomics Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

About Singular Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Singular Genomics Systems at a specified time, usually calculated after every quarter, six months, or one year. Singular Genomics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Singular Genomics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Singular currently owns. An asset can also be divided into two categories, current and non-current.

Singular Genomics Balance Sheet Chart

At present, Singular Genomics' Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Other Liabilities is expected to grow to about 1.3 M, whereas Total Assets are forecasted to decline to about 226.1 M.

Total Assets Short Long Term Debt Total Total Current Liabilities Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Singular Genomics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Singular Genomics Systems books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Singular Genomics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Singular Genomics Systems are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Singular Genomics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Singular Genomics Systems current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Singular Genomics Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	58.8M	75.3M	86.6M	90.9M
Total Assets	328.0M	265.5M	305.3M	226.1M

Short Long Term Debt Total Total Assets

Singular Genomics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.76	0.05	0.81	0.99	0.86	0.97	0.75	-0.16	-0.87	0.98	0.69	0.76	0.89	0.9	0.88	0.97	0.98	-0.83	0.97	-0.78	0.99	0.98	-0.26	0.99	0.75
Short Long Term Debt Total	0.76		-0.36	0.99	0.68	0.48	0.83	1.0	0.51	-0.96	0.84	0.09	1.0	0.74	0.96	0.78	0.62	0.81	-0.78	0.84	-0.33	0.75	0.83	0.34	0.69	1.0
Other Current Liab	0.05	-0.36		-0.25	0.13	0.53	0.04	-0.39	-0.73	0.2	-0.14	0.6	-0.38	-0.3	-0.17	0.14	0.21	-0.01	-0.15	-0.15	-0.48	0.13	0.0	-0.65	0.13	-0.36
Total Current Liabilities	0.81	0.99	-0.25		0.75	0.58	0.89	0.99	0.41	-0.98	0.88	0.2	0.99	0.76	0.98	0.84	0.7	0.85	-0.83	0.87	-0.43	0.81	0.88	0.24	0.76	0.99
Total Stockholder Equity	0.99	0.68	0.13	0.75		0.9	0.96	0.68	-0.27	-0.82	0.94	0.77	0.69	0.87	0.85	0.86	0.99	0.96	-0.8	0.93	-0.84	0.99	0.95	-0.37	1.0	0.67
Other Liab	0.86	0.48	0.53	0.58	0.9		0.85	0.46	-0.49	-0.64	0.74	0.88	0.47	0.61	0.69	0.83	0.93	0.8	-0.8	0.72	-0.92	0.9	0.8	-0.57	0.9	0.47
Net Tangible Assets	0.97	0.83	0.04	0.89	0.96	0.85		0.83	-0.05	-0.92	0.95	0.61	0.83	0.83	0.95	0.88	0.95	0.95	-0.84	0.95	-0.78	0.97	0.96	-0.21	0.96	0.83
Property Plant And Equipment Net	0.75	1.0	-0.39	0.99	0.68	0.46	0.83		0.52	-0.96	0.84	0.08	1.0	0.75	0.95	0.76	0.61	0.8	-0.75	0.84	-0.32	0.74	0.83	0.34	0.68	1.0
Net Debt	-0.16	0.51	-0.73	0.41	-0.27	-0.49	-0.05	0.52		-0.31	0.04	-0.81	0.51	0.0	0.24	-0.03	-0.35	-0.04	-0.01	0.05	0.61	-0.18	0.0	0.92	-0.26	0.52
Retained Earnings	-0.87	-0.96	0.2	-0.98	-0.82	-0.64	-0.92	-0.96	-0.31		-0.93	-0.3	-0.96	-0.81	-0.98	-0.86	-0.77	-0.91	0.85	-0.93	0.47	-0.87	-0.94	-0.16	-0.82	-0.96
Accounts Payable	0.98	0.84	-0.14	0.88	0.94	0.74	0.95	0.84	0.04	-0.93		0.53	0.85	0.92	0.94	0.88	0.9	0.99	-0.83	0.99	-0.63	0.96	0.99	-0.05	0.94	0.84
Cash	0.69	0.09	0.6	0.2	0.77	0.88	0.61	0.08	-0.81	-0.3	0.53		0.09	0.5	0.36	0.56	0.83	0.59	-0.51	0.51	-0.92	0.71	0.57	-0.84	0.77	0.08
Non Current Assets Total	0.76	1.0	-0.38	0.99	0.69	0.47	0.83	1.0	0.51	-0.96	0.85	0.09		0.76	0.96	0.76	0.63	0.81	-0.76	0.85	-0.33	0.75	0.83	0.33	0.69	1.0
Non Currrent Assets Other	0.89	0.74	-0.3	0.76	0.87	0.61	0.83	0.75	0.0	-0.81	0.92	0.5	0.76		0.85	0.81	0.83	0.87	-0.76	0.89	-0.56	0.86	0.87	-0.1	0.87	0.72
Other Assets	0.9	0.96	-0.17	0.98	0.85	0.69	0.95	0.95	0.24	-0.98	0.94	0.36	0.96	0.85		0.9	0.81	0.92	-0.88	0.93	-0.56	0.9	0.94	0.08	0.86	0.95
Long Term Debt	0.88	0.78	0.14	0.84	0.86	0.83	0.88	0.76	-0.03	-0.86	0.88	0.56	0.76	0.81	0.9		0.83	0.89	-0.99	0.84	-0.61	0.92	0.92	-0.08	0.86	0.75
Cash And Short Term Investments	0.97	0.62	0.21	0.7	0.99	0.93	0.95	0.61	-0.35	-0.77	0.9	0.83	0.63	0.83	0.81	0.83		0.92	-0.78	0.89	-0.9	0.97	0.91	-0.46	0.99	0.61
Common Stock Total Equity	0.98	0.81	-0.01	0.85	0.96	0.8	0.95	0.8	-0.04	-0.91	0.99	0.59	0.81	0.87	0.92	0.89	0.92		-0.84	0.99	-0.66	0.98	1.0	-0.1	0.96	0.8
Common Stock Shares Outstanding	-0.83	-0.78	-0.15	-0.83	-0.8	-0.8	-0.84	-0.75	-0.01	0.85	-0.83	-0.51	-0.76	-0.76	-0.88	-0.99	-0.78	-0.84		-0.78	0.57	-0.88	-0.88	0.05	-0.81	-0.75
Short Term Investments	0.97	0.84	-0.15	0.87	0.93	0.72	0.95	0.84	0.05	-0.93	0.99	0.51	0.85	0.89	0.93	0.84	0.89	0.99	-0.78		-0.61	0.95	0.98	-0.04	0.94	0.84
Non Current Liabilities Total	-0.78	-0.33	-0.48	-0.43	-0.84	-0.92	-0.78	-0.32	0.61	0.47	-0.63	-0.92	-0.33	-0.56	-0.56	-0.61	-0.9	-0.66	0.57	-0.61		-0.79	-0.66	0.76	-0.84	-0.32
Other Current Assets	0.99	0.75	0.13	0.81	0.99	0.9	0.97	0.74	-0.18	-0.87	0.96	0.71	0.75	0.86	0.9	0.92	0.97	0.98	-0.88	0.95	-0.79		0.98	-0.27	0.99	0.74
Other Stockholder Equity	0.98	0.83	0.0	0.88	0.95	0.8	0.96	0.83	0.0	-0.94	0.99	0.57	0.83	0.87	0.94	0.92	0.91	1.0	-0.88	0.98	-0.66	0.98		-0.08	0.95	0.82
Total Liab	-0.26	0.34	-0.65	0.24	-0.37	-0.57	-0.21	0.34	0.92	-0.16	-0.05	-0.84	0.33	-0.1	0.08	-0.08	-0.46	-0.1	0.05	-0.04	0.76	-0.27	-0.08		-0.37	0.34
Net Invested Capital	0.99	0.69	0.13	0.76	1.0	0.9	0.96	0.68	-0.26	-0.82	0.94	0.77	0.69	0.87	0.86	0.86	0.99	0.96	-0.81	0.94	-0.84	0.99	0.95	-0.37		0.68
Property Plant And Equipment Gross	0.75	1.0	-0.36	0.99	0.67	0.47	0.83	1.0	0.52	-0.96	0.84	0.08	1.0	0.72	0.95	0.75	0.61	0.8	-0.75	0.84	-0.32	0.74	0.82	0.34	0.68

Click cells to compare fundamentals

Singular Genomics Account Relationship Matchups

Singular Genomics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	30.5M	355.6M	328.0M	265.5M	305.3M	226.1M
Short Long Term Debt Total	9.4M	9.9M	58.8M	75.3M	86.6M	90.9M
Other Current Liab	2.3M	4.4M	(1.6M)	172K	154.8K	147.1K
Total Current Liabilities	3.7M	6.7M	14.1M	18.3M	21.0M	22.1M
Total Stockholder Equity	(51.6M)	336.2M	260.3M	179.0M	205.9M	153.8M
Property Plant And Equipment Net	2.4M	6.1M	56.7M	71.5M	82.2M	86.3M
Net Debt	(2.3M)	(191.1M)	(15.4M)	59.1M	67.9M	71.3M
Retained Earnings	(53.1M)	(151.9M)	(242.8M)	(337.6M)	(303.8M)	(288.6M)
Accounts Payable	427K	2.3M	3.1M	2.6M	3.0M	2.0M
Cash	11.7M	201.0M	74.3M	16.2M	18.7M	17.7M
Non Current Assets Total	2.9M	7.9M	59.5M	73.2M	84.2M	88.4M
Long Term Debt	8.5M	9.9M	10.1M	8.9M	10.2M	8.7M
Cash And Short Term Investments	26.9M	339.2M	244.6M	173.9M	200.0M	182.8M
Common Stock Shares Outstanding	2.3M	2.4M	2.4M	2.4M	2.2M	2.1M
Short Term Investments	15.2M	138.2M	170.3M	157.7M	181.4M	114.9M
Liabilities And Stockholders Equity	30.5M	355.6M	328.0M	265.5M	305.3M	226.1M
Non Current Liabilities Total	78.4M	12.7M	53.5M	68.2M	61.4M	45.5M
Other Current Assets	635K	4.5M	3.6M	3.1M	3.6M	2.7M
Other Stockholder Equity	1.6M	488.2M	503.9M	516.4M	593.9M	317.1M
Total Liab	82.1M	19.5M	67.7M	86.5M	99.4M	72.3M
Net Invested Capital	(42.2M)	346.1M	270.4M	187.9M	216.1M	162.8M
Property Plant And Equipment Gross	2.4M	8.3M	56.7M	79.5M	91.4M	96.0M
Total Current Assets	27.6M	347.8M	268.4M	192.2M	221.1M	194.1M
Accumulated Other Comprehensive Income	17K	(138K)	(837K)	155K	139.5K	146.5K
Non Current Liabilities Other	714K	2.8M	43.5M	650K	747.5K	710.1K
Net Working Capital	23.9M	341.0M	254.3M	173.9M	200.0M	184.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

EBR	Centrais Electricas Brasileiras
HE	Hawaiian Electric Industries
VFC	VF Corporation

When determining whether Singular Genomics Systems offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Singular Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Singular Genomics Systems Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Singular Genomics Systems Stock:

How To Invest In Singular

Details

Is Singular Stock a good investment?

Details

What is Singular Genomics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(34.68)

Revenue Per Share

1.107

Quarterly Revenue Growth

0.459

Return On Assets

(0.24)

Return On Equity

(0.52)

The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Singular Historical Balance Sheet

Singular Genomics Inventory

9.57 Million

About Singular Balance Sheet Analysis

Singular Genomics Balance Sheet Chart

Total Assets

Total Current Liabilities

Singular Genomics balance sheet Correlations

Singular Genomics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Singular Genomics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Common Stock Shares Outstanding	- 0.99	Long Term Debt
Other Assets	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Current Liabilities
Property Plant And Equipment Gross	- 0.96	Retained Earnings
Non Current Assets Total	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Property Plant And Equipment Net